Safety and Efficacy of Iron(III)-hydroxide Polymaltose Complex a review of over 25 years experience

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 6, 2007, Pages 439-452

  Geisser, Peter ^a  

^a Vifor (International) Inc   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ASCORBIC ACID; CYANOCOBALAMIN; FERRITIN; FERROUS FUMARATE; FERROUS SULFATE; FOLIC ACID; HEMATIN; IRON 59; IRON POLYMALTOSE; MALTOFER; PLACEBO; TETRACYCLINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; ERYTHROCYTE; FECES COLOR; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDIGESTION; IRON DEFICIENCY ANEMIA; IRON THERAPY; LASSITUDE; NAUSEA; NONHUMAN; ORANGE JUICE; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; PREGNANT WOMAN; REVIEW; SIDE EFFECT; STOMACH DISEASE; STOMACH PAIN; TOOTH DISCOLORATION; VOMITING;

ANEMIA, IRON-DEFICIENCY; CHILD, PRESCHOOL; CLINICAL TRIALS; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; FEMALE; FERRIC COMPOUNDS; FERROUS COMPOUNDS; FOLIC ACID; HEMOGLOBINS; HUMANS; INFANT; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS;

EID: 34447345399     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296693     Document Type: Article

References (62)

1. Woods S, De Marco T, Friedland M. Iron metabolism. Am J Gastroenterol. 1990; 85: 1-8.
2. Harju E. Clinical pharmacokinetics of iron preparations. Clin Pharmacokinet. 1989; 17: 69-89.
3. Linker CA. Blood. In: Tierney LM, Mcphee SJ, Papadakis MA, eds. Current Medical Diagnosis and Treatment. 36th ed. London: Practice-Hall; 1997. p. 463-465.
4. DeMaeyer EM, Dallman P, Gurney JM, et al. Preventing and controlling iron deficiency anaemia through primary health care. Geneva: World Health Organisation; 1989.
5. Lozoff B, Jimenez E, Wolf AW. Long-term developmental outcome of infants with iron deficiency. New Engl J Med. 1991; 325: 687-694.
6. Cook JD, Skikne BS, Baynes RD. Iron deficiency: the global perspective. In: Hershko CH, Konjin AM, Aisen PH, eds. Progress in Iron Research. New York: Plenum Press; 1994.
7. Adv Exp Med Biol. 1994; 356: 219-228.
8. Agaoglu L, Torun O, Unuvar E, Sefil Y, Demir D. Effects of iron deficiency anemia on cognitive function in children. Arzneimittel-Forschung (Drug Research). 2007; 57(6a): 426-430.
9. Brock C, Curry H, Hanna C, et al. Adverse effects of iron supplementation: a comparative trial of a wax-matrix iron preparation and conventional ferrous sulfate tablets. Clin Ther. 1985; 7: 568-573.
10. Anderson AC. Iron poisoning in children. Curr Opin Ped. 1994; 6: 289-294.
11. Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, Cobaugh DJ, Youniss J, Omslaer JC, May ME, Woolf AD, Benson BE. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2002; 20: 391-452.
12. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. ArzneimittelForschung (DrugResearch). 1992; 42: 1439-1452.
13. Jacobs P, Wood L, Bird AR. Better tolerance of iron polymaltose complex compared with ferrous sulphate in treatment of anaemia. Hematology. 2000; 5: 77-83.
14. Hutchinson C, Al-Ashgar W, Liu DY, Hider RC, Powell JJ, Geissler CA. Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron. Eur J Clin Invest. 2004; 34: 782-784.
15. Geisser P. Iron therapy with special emphasis on oxidative stress. Rorschach (Switzerland): Löpfe-Benz AG; 1998.
16. Geisser P, Müller A. Iron pharmacokinetics after administration of ferric-hydroxide-polymaltose complex in rats. Arzneimittel-Forschung (Drug Research). 1984; 34(11): 1560-1569.
17. Geisser, P. Iron Therapy, Oxidative Stress and Immunology. In: Chandra RK, ed. Nutrition and Immunology in the 21st Century. New Dehli (India)/Ontario (Canada): TSAR Health; 2004. p. 53-65.
18. Geisser P, Müller A. Pharmacokinetics of Iron Salts and Ferric Hydroxide-Carbohydrate Complexes. Arzneimittel-Forschung (Drug Research). 1987; 37: 100-104.
19. Potgieter MA, Potgieter JH, Venter C, Venter JL, Geisser P Effect of oral aluminium hydroxide on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia. A single-centre randomised controlled isotope study. Arzneimittel-Forschung (Drug Research). 2007; 57(6a): 392-400.
20. Potgieter MA, Potgieter JH, Venter C, Venter JL, Geisser P Effect of oral tetracycline on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia. A single-centre randomized controlled isotope study. Arzneimittel-Forschung (Drug Research). 2007; 57(6a): 376-384.
21. Dietzfelbinger H. Bioavailability of bi-and trivalent oral iron preparations. Arzneimittel-Forschung (Drug Research). 1987; 37: 107-112.
22. Heinrich HC. Bioverfügbarkeit und therapeutische Wirksamkeit oraler Eisen(II)-und-(III)präparate. Schweizerische Apotheker-Zeitung. 1986; 124: 1231-1256.
23. Nielsen P, Gabbe EE, Fischer R, Heinrich HC. Bioavailability of iron from oral ferric polymaltose in humans. Arzneimittel-Forschung (Drug Research). 1994; 44: 743-748.
24. EMEA. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London, 26 July 2001. CPMP/ EWP/QWP/1401/98.
25. Geisser P, Philipp E. True iron bioavailability and iron pharmacokinetics. J Pharmacokinet Pharmacodyn. Submitted.
26. Jacobs P, Wormald LA, Gregory MC. Absorption of iron polymaltose and ferrous sulphate in rats and humans. S Afr Med J. 1979; 55: 1065-1072.
27. Jacobs P, Johnson G, Wood L. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose. J Med. 1984; 15: 367-377.
28. Kaltwasser JP Werner E, Nichzial M. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneimittel-Forschung (Drug Research). 1987; 37: 122-129.
29. Eckenved G. Influence of food on the absorption from different types of iron tablets. Scand J Haematol. 1976; 28: 79-88.
30. Werner E, Kaltwasser JP. Orale Eisentherapie. Intestinale Absorption und ihre Beeinflussung durch eine Mahlzeit. Dtsch. med. Wschr. 1977; 102: 1061-1064.
31. Forth W. Iron, bioavailability, absorption, utilization. In: Pharmakologie und Toxikologie. Band 2. Mannheim: Wissenschaftsverlag; 1993.
32. Potgieter MA, Pretorius SG, Jacobs YL, Venter C, Venter JL, Geisser P. Effect of an oral iron(III)-hydroxide polymaltose complex on tetracycline pharmacokinetics in patients with iron deficiency anaemia. Arzneimittel-Forschung (DrugResearch). 2007; 57(6a): 385-391.
33. Lundqvist H, Sjöberg F. Food interaction of oral uptake of iron. A clinical trial using 59Fe. Arzneimittel-Forschung (DrugResearch). 2007; 57(6a): 401-416.
34. Funk F, Canclini, C, Geisser P. Interactions between iron(III)-hydroxide polymaltose complex and commonly used medications. Laboratory studies in rats. Arzneimittel-Forschung (DrugResearch). 2007; 57(6a): 370-375.
35. Tuomainen TP, Nyyssönen K, Porkkala-Sarataho E, et al. Oral supplementation with ferrous sulphate but not with non-ionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation. Nutr Res. 1999; 19: 1121-1132.
36. Mackintosh W, Jacobs P. Response in serum ferritin and haemoglobin to iron therapy in blood donors. Amer J He-matol. 1988; 27: 17-19.
37. Jacobs P, Fransman D, Coglan P. Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blood donors. J Clin Apheresis. 1993; 8: 89-95.
38. Langstaff RJ, Geisser P, Heil WG, et al. Treatment of iron-deficiency anaemia: a lower incidence of adverse effects with Ferrum Hausmann than ferrous sulphate. Brit J Clin Res. 1993; 4: 191-198.
39. Sas G, Nemesanszky E, Bräuer H, et al. On the therapeutic effects of trivalent and divalent iron in iron deficiency anaemia. Arzneimittel-Forschung (Drug Research). 1984; 34: 1575-1579.
40. Schmidt BJ, Morais MB, Fisberg M, et al. Comparagao terapéutica entre o sulfato ferroso e o ferro trivalente em forma de complexo dehidróxido férrico polimaltosado na de-ficiéncia orgánica de ferro. Folha Med. 1985; 90: 25-29.
41. Murahovschi J, Stein ML, Caraffa RC, et al. Tratamento da ferropenia e da anemia ferropenica com o complexo de hi-droxido de ferro polimaltosado por via oral, de crianzas em fase de recuperagao de infecgoes respiratorias. Ensaio du-plo-cego, comparativo com sulfato ferroso. Rev Paul Ped. 1987; 5: 97-104.
42. Devaki PB, Chandra RK, Geisser P Effect of oral supplementation with iron(III)-hydroxide polymaltose complex on the immunological profile of adolescents with varying iron status. Arzneimittel-Forschung (Drug Research). 2007; 57(6a): 417-425.
43. Vetter W, Steurer J. Single-centre, open, randomised, paral-lel-group study comparing the efficacy and tolerability of oral ferric polymaltose complex in doses of 200 mg, 400 mg and 600 mg per day. Clinical Report [internal report]. St. Gallen (Switzerland): Vifor (International) Inc.; 2000.
44. Andrade JVD, Rodrigues PPB, Fontoura IB, DʼnAgnoluzzo R, Horta VF Alves JGB. Tratamento da anemia ferropriva com hidróxido de ferro polimaltosado-Estudo multicéntrico comparativo entre tratamento ministrado com e sem alimentado concomitante. Arq bras Med (Suppl). 1992; 66: 253-258.
45. Rosenberg F, Frigge H, Mickan J, et al. Zur Resorption dreiwertigen Eisens. Therapiewoche. 1979; 29: 3325-3326.
46. Gürer D, Olgun T, Kayaalp N, Nohoglu A. Comparison of the effectiveness of ferrous and ferric irons in the treatment of iron deficiency anaemia. ijisli Etfal Community Hospital, Department of Pediatrics (Turkey); 1998.
47. Haliotis FA, Papanastasiou DA. Comparative study of toler-ability and efficacy of iron protein succinylate versus iron hydroxide polymaltose complex in the treatment of iron deficiency in children. Int J Clin Pharmacol Ther. 1998; 36: 320-325.
48. Geisser P, Hohl H, Müller A. Klinische Wirksamkeit dreier verschiedener Eisenpräparate an Schwangeren. Schweizerische Apotheker-Zeitung. 1987; 14: 393-398.
49. Beruti EJ. Oral treatment of multi-deficiency anaemias of pregnant women with a combination of ferric polymalto-sate, folic acid and vitamin B12 [internal report]. St. Gallen (Switzerland): Vifor (International) Inc.; 1978.
50. Mills KC, Curry SC. Acute iron poisoning. Emerg Med Clin North Am. 1994; 12: 397-413.
51. Ten Kate J, Wolthuis A, Westerhuis B, et al. The iron content of serum ferritin: physiological importance and diagnostic value. Eur J Clin Chem Clin Biochem. 1997; 35: 53-56.
52. Almache ON, Del Águila CM. Estudio controlado de dos compuestos de polimoltosado férrico en el tratamiento de anemia ferropénica en niños de 6 meses a 2 años. Revista del AWGLA. 2005; 1: 31-38.
53. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy: A randomized trial. Obstet Gynecol. 2005; 106: 1335-1340.
54. Kunz J, Billeter U, Rothe E. Multicentre open non-con-trolled Phase III study to document the tolerability and efficacy of Maltofer Fol as an oral solution in the treatment of iron deficiency in pregnant women and the prophylaxis of iron and folic acid deficiency in pregnant women [internal report]. St. Gallen (Switzerland): Vifor (International) Inc.; 2003.
55. Malikova GB, Rassadina MV The effect of the anti-anaemic drug maltofer on iron metabolism indices in breastfeeding mothers and their breast-fed infants. Pediatriya. 2005; 4: 83-86.
56. Soboleva MK. Iron deficiency anaemia in infants: diagnosis and present-day therapy. Voprosy gematologii immunopa-tologii v pediatrii. 2003; 2: 32-37.
57. Kavakli K, Yilmaz D, Cetinkaya B, Balkan C, Sozmen EY, Sa-gin FG. Safety profiles of Fe(2+) and Fe(3+) oral preparations in the treatment of iron deficiency anemia in children. Pediatr Hematol Oncol. 2004; 5: 403-410.
58. Soboleva MK. Iron-deficiency anaemia children and breastfeeding mothers and its treatment and prophylaxis with Maltofer and Maltofer-Fol. Pediatria. 2001; 6: 27-32.
59. Kazyukova TV, Fallukh A, Levina AA, Tsaregorodtseva LV, Vykhristyuk OF, Bimbasova TA, et al. Treatment of iron deficiency anaemia in young children. Pediatriya. 2000; 2: 56-61.
60. Soboleva MK. Efficacy of iron preparations and their side effects in the treatment of iron-deficiency anaemia in young children. Drugs in Paediatrics. 2004; 2: 1-5.
61. Borbolla JR, Cicero RE, Dibildox MM, Sotres RD, Gutiérrez GR. Complejo polimaltosado fèrrico vs sulfato ferroso en el tratamiento de la anemia por deficiencia de hierro en lactantes. Revista Mexicana de pediatria. 2000; 67: 63-67.
62. Sozmen EY, Kavakli K, Cetinkaya B, Akgay YD, Yilmaz D, Aydinok Y Effects of iron(II) salts and iron(III) complexes on trace element status in children with iron-deficiency anemia. Biological Trace Element Research. 2003; 94: 79-85.